Protective and pathogenic roles of cytokines in inflammatory bowel diseases

Journal of Investigative Medicine

Volumn 44, Issue 9, 1996, Pages 516-521

  Neurath, Markus F ^a   Meyer Zum Büschenfelde, Karl Hermann ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

DRUG EFFECT; ENTERITIS; HUMAN; IMMUNOLOGY; INTESTINE MUCOSA; LYMPHOCYTE; MACROPHAGE; MUCOSAL IMMUNITY; REVIEW;

CYTOKINES; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LYMPHOCYTES; MACROPHAGES;

EID: 0030341068     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Mowat AM. The regulation of immune responses to dietary protein antigens. Immunol Today 1987;8:93-8.
2. Beagley KW, Elson CO. Cells and cytokinos in mucosal immunity and inflammation. Gastroenterol Clin North Am 1992;21:347-66.
3. Zeitz M, Greene WC, Petter NJ, James SP. Lymphocytes isolated from the intestinal lamina propria of normal nonhuman primates have increased expression of genes associated with T cell activation. Gastroenterology 1988;94:647-55.
4. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:928-35.
5. Strober W, Neurath MF. Immunological diseases of the gastrointestinal tract. In: Rich RR, ed. Clinical Immunology. St Louis: Mosby, 1995:1401-28.
6. Pirzer U, Schonhaar A, Meyer zum Buschenfelde K-H, Fleischer B. Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet 1991;338:1238-40.
7. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde K-H, Neurath MF. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with IL-10 or antibodies to IL-12. Eur J Immunol. 1996;26:934-8.
8. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde K-H. Tolerance exists towards res dent intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
9. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horvak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
10. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
11. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bahn AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993;75:275-82.
12. Targan SR, Deem RL, Liu M, Wang S, Nel A. Definition of a lamina propria T cell responsive state. Enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway. J Immunol. 1995;154:664-75.
13. Boirivant M, Fuss I, Fiocchi C, Klein JS, Strong SA, Strober W. Hypoproliferative human lamina propria T cells retain the capacity to secrete lymphokines when stimulated via CD2/CD28 signaling pathways. Proc Assoc Am Physicians 1995;108:55-64.
14. Shanahan F. Inflammatory bowel disease: immunology of intestinal diseases. Ann Intern Med 1987;106:853-66.
15. James SP. Remission of Crohn's disease after human immunodeficiency virus infection. Gastroenterology 1988;95:1667-76.
16. Mosmann T. Cytokines and immune regulation. In: Rich RR, ed. Clinical Immunology. St. Louis: Mosby, 1995:217-30.
17. Mosmann T, Sad S. The expanding universe of T-cell subsets: TH1, TH2, and more. Immunol Today 1996;17:138-146.
18. hi CD4+ T cells. Immunity 1994;2:553-62.
19. lo CD4+ T cells are important for the balance between protective and pithogenic cell-mediated immunity. J Exp Med 1994;179:589-600.
20. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5:1461-71.
21. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995;3:171-4.
22. Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med 1993;178:237-46.
23. Fuss I, Neurath MF, Boirivant M, Klein JS, de la Motte C, Strong S, Fiocchi C, Strober W. The lymphokine production of lamina propria CD4+ T cells in Crohn's disease exhibits a TH1-like (IFN-γ) profile, whereas ulcerative colitis manifests a TH2-like (IL-5) profile. J Immunol 1996;157:1261-70.
24. Kusugami K, Matsuura T, West GA, Youngman KR, Rachmilewitz D, Fiocchi C. Loss of IL-2-producing intestinal CD4+ T cells in inflammatory bowel disease. Gastroenterology 1991;101:1594-605.
25. Mullin GE. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992;102:1620-7.
26. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald IT. IL-2- and IFN-γ-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993;78:127-31.
27. Autschbach F, Schurmann G, Qiao L, Merz H, Wallich R, Meuer SC. Cytokine mRNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease. Virchows Arch 1995;426:51-60.
28. Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Stahl PD, Raedler A. Immune response of activated mononuclear phagocytes to interleukin-4 in inflammatory bowel disease. Gastroenterology 1995;108:21-33.
29. Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1995;102:529-37.
30. Casine RV, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995;154:2434-40.
31. Isaaks KL, Sartor RB, Haskill S. Cytokine mRNA profiles in inflammatory bowel disease mucosa detected by PCR amplification. Gastroenterology 1992;103:1587-95.
32. Mahida YR, Wu K, Jewell DP. Enhanced production of Interleukin1-β by mononuclear cells isolated from mucosa with active ulcerative colitis and Crohn's disease. Gut 1989;30:835-8.
33. Mitsuyama K, Toyonaga A, Sasaki E, Watanabe K, Tateishi H, Nishiyama T, Saiki T, Ikeda H, Tsuruta O, Tanikawa K. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol 1994;96:432-6.
34. Sher ME, D'Angelo AJ, Stein TA, Bruns G: Cytokines in Crohn's colitis. Am J Surg 1995;169:133-43.
35. Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of IL-6 production in Crohn's disease. Gastroenterology 1992;102:514-9.
36. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
37. Strober W, Ehrhardt RO. Chronic intestinal inflammation: an unexpected outcome on cytokine or T cell receptor mutant mice. Cell 1993;75:203-5.
38. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.
39. Hammer RE, Maika SD, Richardson JA, Tang YP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: an animal model of HLAB-27-associated human disorders. Cell 1990;63:1099-112.
40. Hollander GA, Simpson SJ, Mizoguchi E, Nichogiannopoulou A, She J, Gutierrez-Ramos J-C, Bhan AK, Burakoff SJ, Wang B, Terhorst C. Severe colitis in mice with aberrant thymic selection. Immunity 1995;3:27-38.
41. Herminston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995;270:1203-7.
42. i2-deficient mice. Nat Genet 1995;10:143-6.
43. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to IL-12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
44. Stuber E, Strober W, Neurath MF. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of TH1-T cells through the inhibition of IL-12 secretion. J Exp Med 1996;183:183-9.
45. Cominelli F. Interleukin-1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990;86:972-80.
46. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, AllenR, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschmann T. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammation. Nature 1992;359:693-9.
47. 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-4.
48. Weiner HL. Oral tolerance. Proc Natl Acad Sci USA 1994;91:10762-5.
49. Miller A, Lider O. Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc Natl Acad Sci USA 1992;89:421-5.
50. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin-4, and prostaglandin E expression in the brain. J Exp Med 1992;176:1355-64.
51. Nagler-Anderson C, Bober A, Robinson M, Siskind G, Thorbecke G. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1983;83:7443-6.
52. Nussenblatt R, Caspi R, Mahdi R, Chan C, Roberge F, Lider O, Weiner HL. Inhibition of S-antigen-induced experimental autoimmune uveoretinitis by oral induction of tolerance by S-antigen. J Immunol 1989;144:1689-99.
53. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J Exp Med 1996;183:2605-16.
54. Brinkmann V, Kristofic C. Regulation by corticosteroids of TH1 and TH2 cytokine production in human CD4+ effector T cells generated from CD45RO- and CD45RO+ subsets. J Immunol 1995;155:3322-8.
55. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
56. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκBα synthesis. Science 1995;270:286-90.
57. Schreiber S, Heinig T, Thiele H-G, Raedler A. Immunoregulatory role of interleukin-10 in patients with inflammatory bowel disease. Gastroenterology 1995;108:1434-44.
58. van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J. Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody. Gastroenterology 1995;109:129-35.